U.S. Markets closed

Bellicum Pharmaceuticals Q4 Earnings Preview

Benzinga Newsdesk

Bellicum Pharmaceuticals, Inc. - Common Stock (NASDAQ: BLCM) announces its next round of earnings this Tuesday, March 12. Here's Benzinga's advanced look at Bellicum's Q4 earnings report.

Earnings and Revenue

Bellicum EPS is expected to be around a loss of 56 cents per share, according to sell-side analysts. Sales will likely be near $1.19 million.

View more earnings on BLCM

In the same quarter last year, Bellicum announced EPS loss of 61 cents. Bellicum's reported EPS has stacked up against analyst estimates in the past like this:


Quarter Q3 2018 Q2 2018 Q1 2018 Q4 2017
EPS Estimate -0.58 -0.55 -0.69 -0.7
EPS Actual -0.55 -0.6 -0.68 -0.61

Stock Performance

Over the last 52-week period, shares are down 61.23 percent. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with Bellicum. The strength of this rating has maintained conviction over the past three months.

Conference Call

Bellicum's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/blcm/mediaframe/29021/indexl.html

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.